Foundation Medicine
Foundation Medicine, Inc. is a biotechnology company based in Cambridge, Massachusetts, that specializes in providing molecular information products for cancer diagnosis and treatment. The company utilizes advanced genomic profiling technologies to analyze tumor specimens, enabling healthcare providers to gain insights into individual patients' cancer profiles. This information assists in optimizing treatment strategies, particularly for targeted therapies and immunotherapies. Foundation Medicine’s product offerings include FoundationOne for solid tumors, FoundationOne Heme for blood-based cancers, and various diagnostic assays to support clinical decision-making in oncology. The company also maintains a knowledgebase, FoundationCORE, to disseminate scientific advancements and strengthen collaborations within the oncology community. Foundation Medicine has established strategic partnerships with major pharmaceutical companies and research organizations to enhance precision medicine initiatives and develop companion diagnostics for specific therapies. Founded in 2009, Foundation Medicine operates as a subsidiary of Roche Holdings, Inc.
Top Stages
3 past transactions
Moffitt Cancer Center
Grant in 2023
Moffitt Cancer Center in Tampa, Florida, has made a lasting commitment to the prevention and cure of cancer, working tirelessly in the areas of patient care, research and education to advance one step further in fighting this disease.
Lexent Bio
Acquisition in 2020
Lexent Bio, Inc. specializes in developing advanced liquid biopsy technology aimed at transforming cancer diagnosis and treatment. Founded in 2014 and based in San Francisco, California, the company focuses on providing clinically actionable insights through its monitoring platform, which leverages low-pass whole-genome sequencing and DNA methylation analysis. This technology enables oncologists to obtain crucial information regarding cancer diagnosis and treatment options while also facilitating the monitoring of patient responses to therapies. By offering a faster and more accurate alternative to traditional imaging methods, Lexent Bio aims to enhance the understanding of treatment efficacy for both clinicians and patients. As of mid-2020, Lexent Bio operates as a subsidiary of Foundation Medicine, Inc.
COTA Healthcare
Series B in 2016
COTA, Inc. is a Boston-based company that specializes in developing a platform designed to provide data and insights related to cancer patients, aimed at guiding treatment decisions. Founded in 2011 by a team of doctors, engineers, and data scientists, COTA utilizes proprietary technology and advanced analytics to transform fragmented electronic health record (EHR) data into cohesive, research-grade information. This platform supports oncology practices and cancer centers by identifying variations in care, thus enabling the design of effective treatment programs and payment models. COTA's solutions serve a diverse range of stakeholders, including healthcare providers, payers, life sciences companies, and the FDA, ultimately striving to enhance patient outcomes and reduce healthcare costs associated with cancer care.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.